معرفی
Dr. Omid Veiseh is a Professor of Bioengineering and CPRIT Scholar in Cancer Research at Rice University, directing the Biotechnology Launch Pad initiative. He leads interdisciplinary research in engineering cell-based therapeutics and biomaterials for diseases like cancer and diabetes. His lab develops implantable systems combining synthetic biology, immunoengineering, and material science to create 'living pharmacies' for real-time biologic production. He has authored over 80 publications and holds 50+ patents, co-founding biotech companies with $500M+ in funding.
Education:
- Ph.D. in Materials Science & Engineering/Nanotechnology, University of Washington (2009)
- Postdoc at MIT/Harvard Medical School under Prof. Robert Langer (2011-2016)
- B.S. in Cell Biology, Western Washington University (2002)
Research Focus: Innovating biomaterials to modulate immune responses, vascularized tissue engineering, and localized drug delivery systems. Key areas include cytokine factories for cancer immunotherapy, anti-fibrotic biomaterials, and implantable bioelectronic systems. His work bridges lab-to-clinic translation through partnerships with industry and clinical networks.
Awards:
- MedTech Boston’s 40 Under 40 (2017)
- Controlled Release Society Fellow
- Member, National Academy of Inventors
Advising & Grants: Leads multi-disciplinary teams with industry and academic collaborators, securing funding from NIH, CPRIT, and private investors. His translational efforts aim to accelerate FDA-approved therapies through the Biotech Launch Pad. Advises students on biomaterials development and preclinical testing.
Labs/Teams: Veiseh Lab at Rice, focused on biomaterials engineering, cell therapies, and biofabrication. Collaborates with MIT, Harvard, and industry partners on clinical trials for IL-2/IL-12 immunotherapies.
